Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology

10-Dec-2009 - Malaysia

CEVEC Pharmaceuticals and the contract manufacturer Inno Biologics Sdn Bhd announced the signing of a strategic license agreement. This license enables Inno Biologics to offer the full potential of production of their diagnostic and preclinical grade material in highest quality with authentic human Glycosylation patterns using the novel and proprietary CAP™ Expression system.

“After launching our new cell line in the U.S. and European market we are delighted to have now our first customers in Asia/Pacific working with our cells. With expression rates and protein quality outperforming any other human system on the market we are proud to have Inno Biologics working with our unique, state of the art cell line,” Wolfgang Kintzel, Managing Director of CEVEC, comments.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?